The Role of MRP in Breast Cancer Prognosis
Author Information
Author(s): K Nooter, G Brutel de la Riviere, MP Look, KE van Wingerden, SC Henzen-Logmans, RJ Scheper, MJ Flens, JGM Klijn, G Stoter, JA Foekens
Primary Institution: University Hospital Rotterdam and Rotterdam Cancer Institute
Hypothesis
Does the expression of multidrug resistance-associated protein (MRP) in primary breast cancer correlate with patient outcomes?
Conclusion
MRP expression is frequently observed in primary breast cancer and may indicate a more aggressive tumor behavior, particularly in patients with small tumors and those receiving certain chemotherapy.
Supporting Evidence
- 34% of the tumors showed positive MRP expression.
- MRP expression was not related to age, menopausal status, or tumor size.
- MRP expression was associated with increased risk for relapse in patients with small tumors.
Takeaway
This study looked at a protein called MRP in breast cancer and found that when it's present, it might mean the cancer is more aggressive and harder to treat.
Methodology
The study analyzed MRP expression in 259 resected invasive primary breast carcinomas using immunohistochemistry and correlated it with patient characteristics and survival outcomes.
Limitations
The study had a limited number of patients and failures in some subgroups, which may affect the power of the analysis.
Participant Demographics
Median age of participants was 59 years, with a range from 25 to 89 years.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CL: 1.2-6.9
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website